γ-Aminobutyric Acid Receptors in Experimental Hepatic Encephalopathy

  • M. L. Zeneroli
  • M. Baraldi
  • E. Ventura


Studies on the pathogenesis of hepatic encephalopathy (HE) following fulminant hepatic failure (FHF) have focused on biochemical changes occurring in blood, in cerebrospinal fluid or in brain with the aim of recognizing the primary factors leading to the central nervous system (CNS) dysfunction of coma. Because of the numerous metabolic abnormalities found in this pathology a congeries of theories has been generated, but none of these is so fully proved as to be accepted.


Hepatic Encephalopathy Gaba Receptor Visual Evoke Potential Glutamic Acid Decarboxylase Fulminant Hepatic Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    D. Keppler, R. Lesch, W. Reutter, and K. Decker, Experimental hepatitis induced by D-galactosamine, Exp. Mol. Path. 9: 279 (1968).CrossRefGoogle Scholar
  2. 2.
    B. L. Blitzer, J. G. Waggoner, E. A. Jones, H. R. Gralnick, D. Towne, V. Weise, I. J. Kopin, I. Walters, P. F. Teichenne, D. Goodman, and P. D. Berk, A model of fulminant hepatic failure in rabbit, Gastroenterology 74: 664 (1978).PubMedGoogle Scholar
  3. 3.
    E. Chirito, C. Lister, and T. M. S. Chang, Biochemical, hematological and histological changes in a fulminant hepatic failure rat model for artificial liver assessment, Artif. Organs 3: 42 (1979).Google Scholar
  4. 4.
    M. L. Zeneroli, A. Penne, G. Parrinello, C. Cremonini, and E. Ventura, Comparative evaluation of Visual Evoked potentials in experimental hepatic encephalopathy and in pharmacologically induced coma-like states in rat, Life Sci., 28: 1507 (1981).PubMedCrossRefGoogle Scholar
  5. 5.
    M. Baraldi, M. L. Zeneroli, P. Ricci, E. Caselgrandi, and E. Ventura, Down regulation of striatal dopamine receptors in experimental hepatic encephalopathy, Life Sci. (in press)Google Scholar
  6. 6.
    J. E. Fischer and R. J. Baldasserini, Pathogenesis and therapy of hepatic coma in: “Progress in Liver Diseases”, H. Popper and F. Schaffer eds., Grune and Stratton, New York (1975).Google Scholar
  7. 7.
    M. L. Zeneroli, E. Ventura, M. Baraldi, A. Penne, E. Messori,and L. Zieve, Ammonia, mercaptans and short chain fatty acids as pathogenetic agents of hepatic encephalopathy: evaluation by visual evoked potentials, Hepatology 2: 532 (1982).Google Scholar
  8. 8.
    H. Conn and M. M. Lieberthal, The syndrome of portal-systemic encephalopathy, in: “The Hepatic Coma Syndromes and Lactulose”. H. Conn and M. M. Lieberthal eds., Williams and Wilkins, Baltimore (1979).Google Scholar
  9. 9.
    W. A. Coob and G. D. Dawson, The latency and form in many of the occipital potentials evoked by bright flashes, J. Physiol. 152: 108 (1960).Google Scholar
  10. 10.
    D. F. Schafer, L. E. Brody, and E. A. Jones, Visual evoked potentials: an objective measurement of hepatic encephalopathy in the rabbit, Gastroenterology 77, A38 (1979).Google Scholar
  11. 11.
    I. Bodis-Wollner, Evoked potentials, Ann. N.Y. Ac. Sci. 388: 1 (1981).Google Scholar
  12. 12.
    M. L. Zeneroli, C. Cremonini, C. Gollini, G. Pinelli, A. Penne, E. Messori, and M. Baraldi, Effects of hyperammoniemia and of hypoglycemia on visual evoked potentials in rat: comparison with hepatic encephalopathy, Riv. Farmacol. Terap. 13: 35 (1982).Google Scholar
  13. 13.
    D. F. Schafer and E. A. Jones, Hepatic encephalopathy and the y-aminobutyric acid neurotransmitter system, Lancet 1: 18 (1982).PubMedCrossRefGoogle Scholar
  14. 14.
    D. F. Schafer and E. A. Jones, Potential neuronal mechanisms in the pathogenesis of hepatic encephalopathy in: “Progress in Liver Diseases”, H. Popper and F. J. Schaffner eds.,Grune and Stratton, New York (1982).Google Scholar
  15. 15.
    R. A. Nicoll, J. C. Eccles, T. Oshima, and F. Rusia, Prolongation of hippocampal postsynaptic potentials by barbiturates, Nature 258: 625 (1975).PubMedCrossRefGoogle Scholar
  16. 16.
    R. H. Evans, Potentiation of the effects of GABA by pentobarbitone, Brain Res. 171: 113 (1979).PubMedCrossRefGoogle Scholar
  17. 17.
    A. Guidotti, M. Baraldi, and E. Costa, 1–4 benzodiazepines and gamma-aminobutyric acid: pharmacological and biochemical correlates, Pharmacology 19: 267 (1979).PubMedCrossRefGoogle Scholar
  18. 18.
    F. Rossi-Fanelli, H. Freund, R. Krause, A. R. Smith, J. H. James, S. Castorina-Ziparo, and J. E. Fischer; Induction of coma in normal dogs by the infusion of aromatic amino acids and its prevention by the addition of branched-chain amino acids, Gastroenterology 83: 664 (1982).PubMedGoogle Scholar
  19. 19.
    A. P. Bernardi, W. Chance, and J. E. Fischer, Depression of neurological function by intraventricular octopamine and tryptophan, Gastroenterology 82: 1222 (1982).Google Scholar
  20. 20.
    L. Zieve, The mechanism of hepatic coma, Hepatology 1: 360 (1981).PubMedCrossRefGoogle Scholar
  21. 21.
    S. Schenker, K. Breen, and A. M. Hoyumpa, Hepatic encephalopathy: current status, Gastroenterology 66: 121 (1974).PubMedGoogle Scholar
  22. 22.
    H. Conn and M. M. Lieberthal, Pathogenesis of portal-systemic encephalopathy, in: “The Hepatic Coma Syndromes and Lactulose”, H. Conn and M. M. Lieberthal eds., Williams and Wilkins, Baltimore (1979).Google Scholar
  23. 23.
    E. Polli, Il coma epatico, in “Quaderni di Neurofarmacologia”, V. Andreoli, A. De Maio, and M. P. Nielsen eds., Ravizza, Milano (1972).Google Scholar
  24. 24.
    A. M. Mans, S. J. Sanders, R. E. Kirsch, and J. F. Biebuyck, Correlation of plasma and brain amino acid and putative neurotransmitter alterations during acute hepatic coma in the rat, J. Neurochem. 32: 285 (1978).CrossRefGoogle Scholar
  25. 25.
    S. S. Oja, P. Kontro, and P. Landesmaki in: “Amino Acids as Inhibitory Neurotransmitters” S.S. Oja, P. Kontro, and P. Landesmaki eds., Gustav Verlag, Stuttgart, New York (1977).Google Scholar
  26. 26.
    M. L. Zeneroli, E. Iuliano, G. Racagni, and M. Baraldi, Metabolism and brain uptake of y-aminobutyric acid in galactosamine-induced hepatic encephalopathy in rats, J. Neurochem. 38: 1219 (1982).PubMedCrossRefGoogle Scholar
  27. 27.
    A. S. Livingstone, M. Potwin, C. A. Goresky, M.H. Finlayson, and E. J. Hinchey, Changes in the blood-brain barrier in hepatic coma after hepatectomy in the rat, Gastroenterology 73: 697 (1977).PubMedGoogle Scholar
  28. 28.
    M. Baraldiand M.L.Zeneroli, 3H-GABA binding in galactosamineHC1 induced hepatic encephalopathy in rat: a denervation supersensitivity phenomenon, Soc. Neuroscience 7: 511A (1981).Google Scholar
  29. 29.
    M. Baraldi and M. L. Zeneroli, Experimental hepatic encephalopathy: changes in y-aminobutyric acid, Science 216: 427 (1982).PubMedCrossRefGoogle Scholar
  30. 30.
    M. Baraldi and M. L. Zeneroli, Experimental hepatic encephalopathy: a model to study a distinct high affinity GABA receptors, in “Dynamics of Neurotransmitter Function” I. Hanin ed., Raven Press, New York, in press.Google Scholar
  31. 31.
    J. I. Waddington and A. J. Cross, Denervation supersensitivity in the striato-nigral GABA pathway,Nature 276: 618 (1978).PubMedCrossRefGoogle Scholar
  32. 32.
    A. Guidotti, K. Gale, A. Suria, and G. Toffano, Biochemical evidence for two classes of GABA receptors in rat brain, Brain Res. 172: 556 (1979).CrossRefGoogle Scholar
  33. 33.
    K. Kuriyama, E. Kuriahara, Y. Iti, and Y. Yoneda, Increase in striatal 3H-Muscimol binding following intrastriatal injection of kainic acid: a denervation supersensitivity phenomenon, J. Neurochem. 35: 343 (1980).PubMedCrossRefGoogle Scholar
  34. 34.
    N. H. Dierner, Glial and neuronal changes in experimental hepatic encephalopathy. A quantitative morphological investigation, Acta Neurol. Scand. 71: 58 (1978).Google Scholar
  35. 35.
    M. Massotti, A. Guidotti, and E. Costa, Characterization of benzodiazepine and y-aminobutyric recognition sites and their endogenous modulators, J. Neurochem. 1: 409 (1981).Google Scholar
  36. 36.
    A. Guidotti, M. Baraldi, A. Leon, and E. Costa, Benzodiazepines: a tool to explore the biochemical and neurophysiological basis of anxiety, Fed. Proc. 39: 3039 (1980).Google Scholar
  37. 37.
    M. Brower, J. W. Ferkany, and S. J. Enna, Biochemical identification of pharmacologically and functionally distinct GABA receptors in rat brain, J. Neuroscience 1: 514 (1981).Google Scholar
  38. 38.
    M. Baraldi, Evidence that benzodiazepine receptors are coupled with high affinity GABA binding sites in rat brain, Neuroscience Letters 10 (Suppl.): S-58 (1982).Google Scholar
  39. 39.
    M. Baraldi, E. Caselgrandi, P. Borella, C. Cremonini, and M. L. Zeneroli, Zinc content in brain tissue and GABA receptor function in experimental hepatic encephalopathy, in: “Application of Behavioral Pharmacology in Toxicology” V. Cuomo and G. Racagni eds., Raven Press, New York, in press.Google Scholar
  40. 40.
    J. Y. Wu and E. Robert, Properties of brain L-glutamate decarboxylase: inhibition studies, J. Neurochem. 23: 759 (1974).PubMedCrossRefGoogle Scholar
  41. 41.
    Th. De Boer, J. Bruinels, and I. L. Bonta, Differential effects of GABA analogues and zinc on glutamate decarboxylase, 4aminobutyric-2-oxoglutaric acid transaminase and succinate semildehyde dehydrogenase in rat brain tissue, J. Neurochem. 33: 597 (1979).PubMedCrossRefGoogle Scholar
  42. 42.
    M. Chvapil, New aspects in the biological role of zinc: a stabilized of macromolecules and biological membranes, Life Sci. 13: 1041 (1973).PubMedCrossRefGoogle Scholar
  43. 43.
    M. Baraldi, E. Caselgrandi, P. Borella, and M. L. Zeneroli, Decrease of brain zinc in experimental hepatic encephalopathy, Brain Res., in press.Google Scholar
  44. 44.
    L. Zieve, W. M. Doizaki, and F. J. Zieve, Synergism between mercaptans and ammonia or fatty acids in the production of coma: a possible role for mercaptans in the pathogenesis of hepatic coma, J. Lab. Clin. Med. 83: 16 (1974).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • M. L. Zeneroli
    • 1
  • M. Baraldi
    • 1
  • E. Ventura
    • 1
  1. 1.Istituti di Clinica Medica III e di FarmacologiaUniversità di ModenaModenaItaly

Personalised recommendations